Alvotech, with its strategic commercialisation partner Advanz Pharma, received EMA approval for Mynzepli (AVT06) in August ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

At an extravagant reception, hotelier Steve Farzam seemed to literally plunge into marriage, appearing to dive from a helicopter in a rainbow parachute onto the grounds of a luxury hotel north of ...

While mRNA-based COVID-19 vaccines are the best known application of the molecule ... "I was shocked to see this, frankly," ...

Frost & Sullivan has named Siemens the 2025 Southeast Asian Company of the Year in the data center infrastructure solutions industry for its outstanding achievements in technological innovation, ...

AEWIN Technologies Co., Ltd (doing business as AEWIN), a leading provider of advanced network appliances and edge computing ...

Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On November 3, 2025, Outlook Therapeutics announced the resubmission of its ...

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan.

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

BioNxt Solutions ( ($TSE:BNXT) ) has provided an announcement. BioNxt Solutions Inc. has received a ‘Readiness to Grant’ notification from the ...